{"title":"Venous thromboembolic complications in patients with severe and extremely severe COVID-19","authors":"M. V. Bychinin, I. Mandel, T. Klypa, P. Avdonin, D. I. Korshunov, T.S. Bobrovitskaya, S. A. Andreichenko","doi":"10.17116/anaesthesiology202104141","DOIUrl":null,"url":null,"abstract":"Objective. To analyze the incidence and predictors of venous thromboembolic complications (VTEC) in COVID-19 patients ad-mitted to intensive care unit (ICU). Material and methods. A retrospective study recruited 200 ICU patients presenting with severe or critical COVID-19. Results. VTEC were found in 67 (33.5%) out of 200 patients. In 63 patients, deep and superficial vein thrombosis was observed. Four patients had pulmonary embolism. In 41 (20.5%) patients, VTEC occurred within the first day after admission to ICU. Patients presenting with VTEC had more extensive lung damage (CT data) and more common need for vasopressors (79.1% vs 59.4%, p=0.005) and mechanical ventilation (89.6% vs 60.2%, p=0.0001). Survival of these patients was lower (23 (34.3%) vs 76 (57.1%), p=0.003). There were significant differences in levels of von Willebrand factor antigen (vWF: Ag), interleukin 6 (IL-6), antithrombin III (AT III) and protein C. According to ROC analysis, vWF: Ag above 455% (AUC — 0.852 (0.69;1.00), p=0.008) was highly predictive for the risk of VTEC after 1 and 7 days. AT III below 72% (AUC — 0.77 (0.55;0.99), p=0.04) and IL-6 above 256 pg/ml (AUC — 0.85 (0.65;1.00), p=0.053) were prognostic factors of VTEC after the first day. Protein C below 81.5% at admission (AUC — 0.79 (0.59-0.99), p=0.042) was predictive regarding VTEC by the seventh day. Conclusion. Incidence of VTEC in ICU patients was 33.5%. In 60% of patients, VTEC developed before admission to ICU. vWF: Ag, AT III, IL-6, and protein C serve as predictors of VTEC in patients with severe or critical COVID-19. © 2021, Media Sphera Publishing Group. All rights reserved.","PeriodicalId":297480,"journal":{"name":"Anesteziologiya i reanimatologiya","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anesteziologiya i reanimatologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/anaesthesiology202104141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
重症和极重症COVID-19患者的静脉血栓栓塞并发症
目标。目的分析2019冠状病毒病疫情(COVID-19)重症监护病房(ICU)患者静脉血栓栓塞并发症(VTEC)的发生率及预测因素。材料和方法。一项回顾性研究招募了200名重症或危重型COVID-19 ICU患者。结果。200例患者中有67例(33.5%)出现VTEC。63例患者出现深、浅静脉血栓形成。4例患者有肺栓塞。41例(20.5%)患者在入住ICU后第一天内发生VTEC。出现VTEC的患者有更广泛的肺损伤(CT数据),更需要血管加压剂(79.1% vs 59.4%, p=0.005)和机械通气(89.6% vs 60.2%, p=0.0001)。这些患者的生存率较低(23例(34.3%)vs 76例(57.1%),p=0.003)。血管性血友病因子抗原(vWF: Ag)、白细胞介素6 (IL-6)、抗凝血酶III (AT III)、蛋白c水平差异有统计学意义。ROC分析显示,vWF: Ag在455%以上(AUC - 0.852 (0.69;1.00), p=0.008)对第1、7天发生VTEC的风险具有高度预测作用。atiii低于72% (AUC - 0.77 (0.55;0.99), p=0.04)、IL-6高于256 pg/ml (AUC - 0.85 (0.65;1.00), p=0.053)是第1天后VTEC的预后因素。入院时蛋白C低于81.5% (AUC - 0.79 (0.59-0.99), p=0.042)可预测第7天的VTEC。结论。ICU患者VTEC发生率为33.5%。60%的患者在进入ICU前出现VTEC。vWF: Ag、AT III、IL-6和蛋白C可作为重型或危重型COVID-19患者VTEC的预测指标。©2021,Media Sphera出版集团。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。